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Abstract
Background: Protein homeostasis in the endoplasmic reticulum (ER) has recently emerged as a therapeutic target for cancer
treatment. Disruption of ER homeostasis results in ER stress, which is a major cause of cell death in cells exposed to the
proteasome inhibitor Bortezomib, an anti-cancer drug approved for treatment of multiple myeloma and Mantle cell
lymphoma. We recently reported that the ERAD inhibitor Eeyarestatin I (EerI) also disturbs ER homeostasis and has anti-
cancer activities resembling that of Bortezomib.
Methodology and Principal Findings: Here we developed in vitro binding and cell-based functional assays to demonstrate
that a nitrofuran-containing (NFC) group in EerI is the functional domain responsible for the cytotoxicity. Using both SPR
and pull down assays, we show that EerI directly binds the p97 ATPase, an essential component of the ERAD machinery, via
the NFC domain. An aromatic domain in EerI, although not required for p97 interaction, can localize EerI to the ER
membrane, which improves its target specificity. Substitution of the aromatic module with another benzene-containing
domain that maintains membrane localization generates a structurally distinct compound that nonetheless has similar
biologic activities as EerI.
Conclusions and Significance: Our findings reveal a class of bifunctional chemical agents that can preferentially inhibit
membrane-bound p97 to disrupt ER homeostasis and to induce tumor cell death. These results also suggest that the AAA
ATPase p97 may be a potential drug target for cancer therapeutics.
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Introduction
The endoplasmic reticulum (ER) is a major site of protein
folding and assembly in eukaryotic cells. Although many chap-
erones are present in the ER to assist proteins in folding, misfolded
polypeptides are frequently produced, disturbing ER homeostasis.
The accumulation of misfolded proteins in ER triggers ER stress, a
condition that activates several signaling pathways collectively
termed unfolded protein response (UPR) [1,2]. As a major me-
chanism that adapts cells to ER stress, UPR promotes the
elimination of misfolded proteins from the ER. This is critical for
cell vitality, particularly for those carrying high secretory loads.
Moreover, UPR is often activated in tumor tissues due to the
hypoxia condition under which cancer cells are grown [3,4] and
this mild UPR activation is believed to promote cancer pro-
gression as it helps to improve ER fitness and overall cell vitality
[5,6,7,8]. On the other hand, if UPR fails to rectify the folding
problem as often seen in damaged or aged tissues or cells over-
exposed to pharmacological ER stressors, misfolded proteins can
accumulate beyond a reversible point. This causes an irreversible
disruption of ER homeostasis [9]. Signaling processes associated
with programmed cell death are then activated [10,11,12,13].
Healthy cells maintain ER homeostasis by delicately monitoring
the load of proteins into the ER, fine-tuning the ER folding
capacity, and by timely removing misfolded proteins from the ER
[1,2,14,15]. The elimination of misfolded ER proteins is achieved
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process, ER chaperones recognize terminally misfolded proteins
and target them to sites in the ER membrane where they are
subsequently transferred across the membrane to enter the cytosol.
Ubiquitin E3 ligases associated with the ER membrane then
catalyze the polymerization of ubiquitin chains on substrates [16].
This allows substrates to be extracted from the ER membrane by a
cytosolic AAA ATPase named p97/VCP, which, together with the
associated cofactors, shuttles the substrates to the 26S proteasome
for degradation [17,18].
The diverse misfolding signals present in ERAD substrates
necessitate the involvement of multiple mechanisms during the
initiate stage of retrotranslocation. Indeed, many ER chaperones
have been implicated in substrate recognition for distinct classes of
misfolded proteins, and several retrotranslocation routes have
been proposed to mediate the transfer of different substrates across
the ER membrane [17,18,19]. Along the same line, a handful of
E3 ligases each serve a cohort of client substrates to decorate them
with polyubiquitin chains [20,21]. However, in sharp contrast to
the mechanistic diversity in the upstream steps of ERAD, the
downstream events appear highly unified as almost all ERAD
substrates tested to date use the p97 ATPase for membrane
extraction and the proteasome for degradation [22,23]. Accord-
ingly, inhibition of p97 or the proteasome usually has a more
pronounced effect on ER homeostasis than interference with
molecules acting in upstream steps.
Given the critical role of ERAD in regulating ER homeostasis, it is
conceivable that defects in this process can have significant impact on
cell viability, particularly for cells bearing a heavy secretory burden.
Accordingly, the ERAD pathway has emerged as a potential target
for pharmacological intervention with certain types of tumors. For
example, the proteasome inhibitor bortezomib (Velcade
TM) has been
approved for clinical treatment of multiple myeloma and Mantle cell
lymphoma (MCL) [24]. The anti-cancer activity of bortezomib can
be, at least in part, attributed to ER stress induction as a result of its
inhibitory role on ERAD [25,26,27,28,29,30]. Moreover, we recently
reported that the ERAD specific inhibitor Eeyarestatin I (EerI) can
induces cell death in hematologic cancer cells via a mechanism
similar to that of bortezomib [31,32]. Specifically, both EerI and
bortezomib induce ER stress, which activates the expression of
severalCREB/ATF transcriptionfactorsincludingATF4andATF3.
EerI and bortezomib also cause the accumulation of polyubiquiti-
nated proteins in cells, leading to a compensatory loss of mono-
ubiquitinated histone H2A, an epigenetic mark for transcription
repression. ATF4 and ATF3 cooperate with this epigenetic
derepression mechanism to upregulate the expression of NOXA, a
BH3 domain-containing proapoptotic protein [32]. In this study, we
dissect the molecular mechanism underlying the biological action of
EerI. Our results indicate that EerI is a bi-modular compound that
comprises of two functionally independent domains. An aromatic
module in EerI targets it to membranes, allowing a nitrofuran-
containing (NFC) module to directly bind to p97 and to interfere with
its ER-associated functions. As a result, EerI is a much more specific
disruptor of ER homeostasis compared to a compound that only has
the NFC domain. These findings elucidate the mechanism by which
EerI acts to inhibit ERAD and to induce cell death, and reveal a
potential approach to improve drug specificity for cancer therapy that
targets ER homeostasis.
Results
EerI interacts directly with p97
EerI was previously found in association with a p97-containing
protein complex in EerI-treated cell extract [31], but whether EerI
can directly target p97 was unclear. We therefore tested whether
EerI could bind recombinant p97 purified from E coli. using
surface plasma resonance (SPR). When EerI was injected into a
CM5 chip immobilized with p97, it generated a concentration
dependent response (Figure S1). Plotting the measured response
relatively to the calculated maximum response (Rmax) gave rise to
an estimated Kd of 5–10 mM (Figure 1a, b). To understand which
domain in p97 was critical for EerI interaction, we tested the
binding of EerI with two p97 mutants that lacked either the N-
terminal co-factor binding domain (p97DN) or the second ATPase
domain (p97DD2). The results showed that EerI had similar
affinity to wild type and mutant p97 proteins (Figure 1a, b, data
not shown). We concluded from these results that EerI could
directly bind p97 most likely at a site in the D1 ATPase domain.
To understand how EerI binding might affect p97 function, we
measured the in vitro ATPase activity of p97 in the presence of
EerI, but found that EerI had no effect on the p97 ATPase activity
(data not shown). We next tested whether binding of EerI to p97
could alter its conformation, which usually resulted in a change in
sensitivity to protease digestion. This approach has been used to
demonstrate an ATP-induced conformational change in p97 [33].
Interestingly, pre-incubation of EerI with purified p97 caused a
delay in the proteolysis of two p97 fragments by trypsin (Figure 1c).
This result confirms that EerI can directly interact with p97, and
suggests that a conformational change might occur to p97 upon
binding to EerI. We also found that in EerI-treated cells a fraction
of p97 displayed reduced motility on SDS-PAGE gel. This effect
was specific as no such high molecular weight species could be
detected for several other ATPases in EerI-treated cells (Figure 1d).
Together, our results indicate that EerI may alter p97 conforma-
tion to form non-functional p97 oligomers in cells (with a small
fraction of such oligomers being resistant to SDS treatment).
Structure-activity relationship analysis of EerI
To further understand the chemical basis of EerI action, we
divided EerI into two structural subunits defined as a nitrofuran-
containing (NFC) moiety and an aromatic domain, respectively
(Figure 2a). We compared the cytotoxicity of EerI to that of 5-NA
(5-nitrofuryl-acrolein) and CBU-002, which corresponded to these
two subunits. JEKO-1 cells, a MCL-derived cancer cell line, were
treated with these compounds and cell viability was measured by a
colorimetric assay using MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide, a tetrazole). EerI induced cell death
in JEKO-1 cells with an IC50 of 461.2 mM, as demonstrated
previously [32]. 5-NA was also toxic with a moderately reduced
IC50 (,1 mM), whereas CBU-002 was completely inactive
(Figure 2b). We next tested whether 5-NA and CBU-002 could
influence the expression of ATF3, ATF4 and NOXA, as has been
demonstrated for EerI [32]. Immunoblotting experiments revealed
that like EerI, 5-NA upregulated the expression of ATF3, ATF4,
and NOXA. By contrast, CBU-002 lacked this activity (Figure 2c,
Figure S2). We also tested which of these domains were essential
for ERAD inhibition by monitoring the degradation of MHC class
I heavy chain in US11-expressing cells treated with these
compounds. US11 is a human cytomegalovirus-encoded protein
that co-opts the ERAD pathway to degrade newly synthesized
MHC class I heavy chain at the ER membrane [34]. Pulse chase
experiments showed that cells treated with 5-NA exhibited a
significant delay in the turnover of MHC class I heavy chain
similarly to cells treated with EerI, whereas CBU-002 had no effect
(Figure S3). Together, these results strongly suggest that the NFC
domain is the functional group responsible for the ERAD inhi-
bition and cytotoxic activities of EerI.
EerI Targets Membrane-Associated p97
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We hypothesized that EerI might bind p97 via the NFC
domain, which would explain why these two compounds have
similar activities in cells. The molecular weight of 5-NA is too
small for SPR analysis. We therefore conjugated a biotin moiety to
5-NA to generate a biotinylated NFC domain (B-NFC) (Figure 3a).
This allowed us to immobilize the NFC domain on avidin-
conjugated beads and test its binding to purified p97 by co-
precipitation. We used biotin as a negative control, which under
our assay condition precipitated a small amount of p97, pre-
sumably due to non-specific interaction. B-NFC, however,
consistently precipitated more p97 (Figure 3b). Consistent with
Figure 1. EerI targets the p97 ATPase. a, Purified wild type and mutant p97 proteins used in the binding experiments. b, Surface plasmon
resonance analyses of p97-EerI interaction. Where indicated, a mutant p97 lacking its N-terminal domain (p97 DN) was also tested. The binding
signals relative to the calculated Rmax from three independent experiments were plotted. Error bar, SD (n=3). c, EerI alters p97 conformation. p97
was incubated with trypsin in the presence or absence of EerI. The digested samples were analyzed by SDS-PAGE and silver staining. Arrows indicate
p97 fragments partially protected by EerI. The bracket indicates p97 degradation products. d, Whole cell extracts from cells treated with EerI for the
indicated time periods were analyzed by immunoblotting with the indicated antibodies. The arrow indicates a species of slow migrating p97 caused
by EerI treatment.
doi:10.1371/journal.pone.0015479.g001
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PLoS ONE | www.plosone.org 3 November 2010 | Volume 5 | Issue 11 | e15479Figure 2. Structure activity relationship (SAR) analysis of EerI. a, EerI can be divided into a nitrofuran-containing (NFC) and an aromatic
domain, which is represented by compounds CBU-002 and 5-NA (5-nitrofuryl-acrolein), respectively. b, Cytotoxic activity of EerI, 5-NA and CBU-002 in
JEKO-1 cells as determined by a MTT assay. Error bar, SD (n=3). c, The induction of ER stress and NOXA expression requires the NFC domain of EerI.
Whole cell extracts from JEKO-1 cells exposed to the indicated agents (10 mM for EerI, CBU002, and 2.5 mM for 5-NA) were subjected to
immunoblotting analyses.
doi:10.1371/journal.pone.0015479.g002
Figure 3. EerI interacts with p97 via the NFC domain. a, The structure of biotinylated NFC (B-NFC). b, Monomeric avidin beads immobilized
with CBU-032 or biotin were incubated with the indicated recombinant proteins. The bound materials were eluted with biotin and analyzed by SDS-
PAGE and immunoblotting. c,A si nb, except that the indicated His-tagged proteins were tested.
doi:10.1371/journal.pone.0015479.g003
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terminal domain (p97DN) or the D2 ATPase domain (p97DD2)
also bound to 5-NA (Figure 3b). This interaction was specific to
p97 as a homologous AAA ATPase termed NSF (N-ethylmalei-
mide-sensitive factor) did not show significant binding to B-NFC,
neither did the heat shock protein Hsp70 (Figure 3c). These results
demonstrate that EerI can directly interact with p97 via the NFC
domain.
Target specificity of EerI in cells
To further confirm that both EerI and 5-NA can influence p97
function in cells, we compared the gene expression pattern of EerI-
treated cells to that of 5-NA-treated cells using whole genome array
hybridization. We presumed if two chemicals target a same gene, the
change in gene expression profile in response to these compounds
should overlap significantly and genes affected by these compounds
should be similarly influenced when the target gene is inhibited by a
siRNA-mediated knock down approach. We chose 293T cells for this
study because 293T cells are highly transfectable, making them
well suited for genetic manipulation by siRNA. 5-NA treatment
dramatically altered the gene expression landscape, resulting in
changes in the expression of a large number of genes. Interestingly,
the number of genes affected by EerI was significantly smaller
(Figure 4a; Table S1). As expected, a large number of genes affected
by EerI were similarly affected by 5-NA. We defined these genes as
cohort (i). Pathway analyses showed that UPR-associated genes were
enriched in this cohort. By contrast, genes only affected by EerI
(cohort ii) or 5-NA (cohort iii) did not display the signature of UPR
activation.Instead,theyrepresented otherpathways unrelatedto ER
homeostasis (Figure S4; unpublished data). These results suggested
that 5-NA has a broader impact on cell physiology than EerI,
suggesting that it may have additional targets other than p97. The
conjugation of the aromatic module to 5-NA seems to restrict its
action,makingERaprimarytargetofthe resultingcompound EerI.
To test whether the gene expression signature shared by 5-NA
and EerI was indeed a result of p97 inhibition, we knocked down
Figure 4. p97 is a target of both EerI and 5-NA in cells. a, 5-NA has a broader effect on gene expression than EerI. The number of genes up- or
down-regulated by at least 2-fold upon treatment with EerI (10 mM, 10 h) or 5-NA (10 mM, 10 h) in 293T cells was plotted. These genes can be divided
into three categories including 29 genes affected by both EerI and 5-NA (i), 25 genes affected only by EerI (ii) and 306 genes affected only by 5-NA
(iii). b, Knock-down of p97 inhibits the degradation of TCRa-YFP as determined by flow cytometry. A fraction of the cells were used to verify the
knock-down efficiency by immunoblotting with a p97 antibody. c, d, The effect of p97 depletion on the expression of EerI and 5-NA signature genes.
c, The expression of selected genes in the categories i (8 genes, blue dots) and ii (7 genes, red dots) was determined by qRT-PCR using RNA prepared
from p97 knock-down (k.d.) and control cells. The fold change upon p97 depletion was plotted against EerI-induced fold change. Error bars, SD (n=3)
d, The expression of 4 genes in the category (iii) in p97 knock-down cells, or cells exposed to EerI (10 mM) or 5-NA (10 mM) was determined by qRT-
PCR. Untreated cells were used to determine the basal expression of these genes, which was used to calculate the fold change.
doi:10.1371/journal.pone.0015479.g004
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by immunoblotting with an anti-p97 antibody and by monitoring
the stabilization of the model ERAD substrate TCRa in p97
depleted cells (Figure 4b). We analyzed the effect of p97 depletion
on the expression of representative genes upregulated by EerI and
5-NA including 8 genes in cohort (i), 7 genes in cohort (ii), and 4
genes in cohort (iii). qRT-PCR analyses showed that all genes
except for one in cohort (i) were significantly induced upon p97
depletion (.twofold). By contrast, only 2 out of the 7 genes in
cohort (ii) were significantly upregulated in p97 knock-down cells
(Figure 4c), and none of the genes tested in cohort (iii) were
induced by knock-down of p97 (Figure 4d). These results confirm
that p97 is a target of both EerI and 5-NA. Because the expression
of more than 50% of EerI signature genes (cohort i) are similarly
affected by p97 depletion, p97 appears to be a major target of
EerI. By contrast, the majority of the 5-NA-affected genes (cohort
iii) do not seem to result from p97 inhibition. Thus, 5-NA must
have additional targets other than p97 in cells.
The aromatic module recruits EerI to the ER membrane
To understand how the aromatic domain improves EerI target
specificity, we examined the subcellular localization of EerI and 5-
NA, taking advantage of their intrinsic fluorescence properties
[31]. CBU-002 was used as a negative control because it was not
fluorescent in vitro and failed to generate a fluorescence signal in
cells (Figure 5a). 5-NA-treated cells showed a uniform staining
pattern with some punctae (Figure 5b), suggesting that 5-NA
was ubiquitously distributed throughout a cell. By contrast, EerI-
treated cells displayed a strong fluorescence signal in a perinuclear
reticulum-like pattern, indicative of ER localization (Figure 5c, d).
EerI also labeled some vesicles in a perinuclear region that might
be derived from the endocytic system (Figure 5c). Consistent with
the localization study, we found that in EerI-treated cells, the SDS-
resistant p97 oligomer species was detectable only in the
membrane fraction but not in the cytosol fraction (Figure 5e).
Together, these results suggest that EerI can associate with the ER
membrane to selectively interfere with the function of membrane-
associated p97.
To further characterize the membrane association of the
aromatic domain of EerI, we replaced the NFC domain with
several aldehydes that might give rise to a stronger fluorescence
signal. We predicted that the resulting compounds were likely to
be non-toxic as they did not contain the NFC moiety, but they
should be localized to the ER if the aromatic domain of EerI was
capable of binding to the ER membrane. One of the resulting
compounds CBU-059 (Figure 6a) indeed produced a stronger
fluorescence signal than EerI and had little effect on the viability of
JEKO-1 cells (Figure 6b). When exposed to CBU-059, cells
displayed perinuclear ER-like staining pattern resembling EerI-
treated cells (Figure 6c). Double labeling experiment showed that
CBU-059 co-localized with Derlin-1 (Figure 6d), an ER resident
protein [35,36]. These results demonstrate that the aromatic
domain in EerI is sufficient to recruit EerI to the ER membrane.
Identification of a new bifunctional ERAD inhibitor
The bi-modular nature of EerI predicts that it should be
possible to replace the aromatic domain of EerI with a structurally
simpler membrane-targeting group, which should give rise to a
compound with similar activity to EerI. Developing a simpler
compound with similar activity as EerI is a critical issue because of
the difficulty in synthesizing EerI in large scale. We therefore
generated a chemical library that carried the same NFC domain
but with varied benzene-containing groups. We used the
cytotoxicity assay as a first screen, which demonstrated that a
Figure 5. EerI is associated with the ER membrane. a–c, HeLa cells were treated with the indicated compound (10 mM, 1 h) and imaged with a
fluorescence microscope. Arrows in c indicate some EerI-stained vesicles that may be derived from the ER or the endocytic system. d, An enlarged
view of the indicated area in c showed the localization of EerI to a perinuclear reticulum-like membrane compartment in cells. N, nucleus. e, p97
preferentially affects membrane associated p97. 293T cells were either untreated or treated with EerI (10 mM 6 h). Cells were fractionated into
membrane and cytosol fractions. Proteins extracted from these fractions were analyzed by immunoblotting with the indicated antibodies. Note that
the slow migrating p97 species (indicated by the arrow) induced by EerI is primarily in the membrane fraction.
doi:10.1371/journal.pone.0015479.g005
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S2), consistent with the idea that the NFC domain was responsible
for the cytotoxicity. We chose one of these chemicals designated as
CBU-028 for further characterization because its cytotoxicity in
JEKO-1 cells was identical to that of EerI (Figure 7a, b).
We first tested whether CBU-028 could have an inhibitory
effect on ERAD using the model substrate TCRa. Cells stably
expressing YFP-tagged TCRa were treated with EerI and CBU-
028. The substrate TCRa-YFP was immunoprecipitated from cell
extracts under denaturing condition. Immunoblotting showed that
EerI and CBU-028 stabilized TCRa to a similar degree.
Importantly, a significant fraction of TCRa in CBU-028-treated
cells carried polyubiquitin conjugates just like in EerI-treated cells
(Figure 7c). The ubiquitin chains on TCRa from CBU-028-
treated cells appeared to be longer than that in EerI-treated cells,
which might be due to small differences in the inhibitory kinetics
or unknown off-target effect of these compounds (see below). Thus,
CBU-028 can inhibit ER-associated protein degradation at a step
similar to EerI. Importantly, CBU-028 also upregulated the
expression of the ER stress-associated transcription factors ATF3
and ATF4, caused accumulation of polyubiquitinated proteins and
downregulation of ubiquitinated histone H2A (Figure 7d). These
changes were previously reported in EerI-treated cells, suggesting
that CBU-028 has biological activities similar to EerI. Accordingly,
CBU-028 also activated NOXA expression (Figure 7d), and a
JEKO-1 derived cell line stably expressing a NOXA shRNA was
more resistant to CBU-028-induced cell death (data not shown).
Target specificity and localization of CBU-028
To define the target specificity of CBU-028, we performed the
whole genome expression microarray analysis for CBU-028-
treated 293T cells and compared the CBU-028’s effect on gene
expression to that of EerI or 5-NA. These analyses revealed that
CBU-028 had smaller impact on gene expression than 5-NA,
although it still affected more genes than EerI (Figure 8a; Table
S1). A close examination of genes whose expression was
significantly altered by these compounds revealed that CBU-028
was more similar to EerI than 5-NA (Figure 8a–c). Taking the
upregulated genes as an example, all but one gene activated by
EerI was also induced by CBU-028 (Figure 8a), and the fold
induction by these two compounds correlated precisely with each
other (Figure 8b). By contrast, 61% of the CBU-028-induced genes
were not affected by 5-NA, and an even larger percentage of 5-NA
upregulated-genes displayed no significant change in cells treated
with CBU-028 (Figure 8a). Clustering analysis of significant genes
(including both up- and down-regulated genes, fold change $2.0;
p value #0.05) further confirmed that CBU-028 was more closely
related to EerI than to 5-NA (Figure 8c). Together, these results
Figure 6. The aromatic domain targets EerI to the ER membrane. a, The structure of CBU-059. b, cytotoxicity of CBU-059. c, CBU-059 stains a
perinuclear reticulum-like membrane compartment. HeLa cells stained with CBU-029 (3 mM, 1 h) were imaged by a fluorescence microscope using a
FITC filter set. d, CBU-029 co-localizes with the ER membrane protein Derlin-1.
doi:10.1371/journal.pone.0015479.g006
EerI Targets Membrane-Associated p97
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e15479suggested that CBU-028 has improved target specificity when
compared to 5-NA. As a result, it has activities more closely
resembling EerI.
We next examined the subcellular distribution of CBU-028. Like
EerI, CBU-028 was also autofluorescent, but the fluorescence
intensity was ,5fold less than EerI (unpublished data). Nonetheless,
cells treated with CBU-028 displayed detectable fluorescence signals
in a perinuclear reticulum-like pattern resembling that in EerI-
treated cells (Figure 8d). To further confirm the association of CBU-
028 and EerI in membranes, we treated cells with these compounds
or 5-NA and then permeabilized cells using a low concentration of
the detergent digitonin. Cells were then fractionated into a soluble
fraction containing the cytosol and a pellet fraction containing the
ER membrane and nuclei. The fluorescence signal in these fractions
was measured and the ratio between the signal in the pellet and that
in supernatant fractions was calculated. Consistent with the imaging
experiments, the fluorescence signal of 5-NA was not significantly
concentrated in the membrane pellet fraction (Figure 8e). The
,1.8foldenrichmentinthe pellet fraction for5-NAwaslikelycaused
by the nucleus-localized 5-NA. By contrast, the EerI fluorescence
signal was dramatically enriched in the pellet fraction (.9fold
enrichment). CBU-028 also showed ,3.2fold enrichment in the
membrane fraction. Although the membrane enrichment of CBU-
028 was less significant than EerI, our gene expression analyses and
activity studies suggest that the moderate enrichment of CBU-028 to
the ER membrane is sufficient to allow CBU-028 to acquire similar
activities as EerI and to obtain improved target specificity.
Discussion
EerI is a bifunctional inhibitor that has an ER targeting
domain
EerI is the only known chemical inhibitor of the ERAD
pathway [31,37], but the mechanism of its action was unclear. In
this study, we demonstrate that EerI is comprised of two functional
domains, a nitrofuran-containing (NFC) domain and an aromatic
domain. The NFC domain of EerI is essential for its ERAD
inhibitory and cytotoxic activities. The aromatic domain of EerI is
non-toxic by itself, but it can recruit EerI to the ER membrane.
Since the aromatic domain of EerI can be replaced with a
structurally distinct membrane-targeting group and the resulting
compound retains almost all the activities of EerI, we assume that
the major contribution of this domain is to localize EerI to the ER
membrane. The functions of the two EerI subdomains can be
uncoupled as they can be individually manipulated without
affecting the activity of the other. For example, the NFC domain
remains cytotoxic when conjugated to diverse hydrazines. Con-
versely, replacement of the NFC domain in EerI with another
aldehyde can abolish its cytotoxic activity without changing the
ER localization. These results reveal a novel chemical structural
element that can be used to target small molecule inhibitors to the
ER membrane. Given that ER homeostasis has emerged as an
important therapeutic target for cancer treatment, our findings
may aid the development of new anti-cancer drugs that target ER-
associated functions. For example, several ER membrane-
anchored signaling molecules including Ire1 and PERK are now
being evaluated as potential anti-cancer targets [8]. Bi-modular
compounds comprising an inhibitory ‘‘warhead’’ that targets these
signaling molecules and an ER-localizing moiety such as the one in
EerI may be superior to non-localized inhibitors as the former may
have less undesired off-target effects (see below). Our study also
shows that when conjugated to a non-toxic fluorescent unit, the
aromatic domain of EerI can be used as a fluorescent probe to
label the ER with little effect on cell growth. In this regard, CBU-
059 and compounds of its class may be well suited for studying ER
morphology and functions in live cells.
EerI interacts with p97 via the NFC domain
We identify the p97 ATPase as a target of EerI and show that
the nitrofuran domain in EerI is required for interaction with p97.
The binding appears to occur to the D1 domain of p97. It is
Figure 7. CBU-028 has biologic activities resembling EerI. a, Structure of CBU-028. b, CBU-028 has a similar cytotoxic activity as EerI in JEKO-1
cells. Cells were treated with the indicated compounds and cell viability was measured by a MTT assay. Error bar, SD (n=3). c, CBU-028 stabilizes the
ERAD substrate TCRa-YFP in polyubiquitinated forms. 293T cells stably expressing TCRa-YFP were treated with the indicated compounds (10 mM) or
as a control with DMSO for 10 h. TCRa-YFP was immunoprecipitated from the cell extract. The precipitated material was analyzed by SDS-PAGE and
immunoblotting. d, CBU-028 has similar biological activities as EerI. JEKO-1 cells were treated with 10 mM CBU-028 for the indicated time periods.
Whole cell extract was analyzed by immunoblotting with antibodies against the indicated proteins.
doi:10.1371/journal.pone.0015479.g007
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PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e15479Figure 8. Target specificity and subcellular distribution of CBU-028. a, Microarray analyses of gene expression profiles of EerI-, 5-NA-, and
CBU-028-treated 293T cells. Shown is a Venn diagram indicating the numbers of genes significantly induced (.2 fold, p value ,0.05) by these
compounds. b, EerI-activated genes are also similarly induced by CBU-028. The fold change for EerI-induced genes was plotted against the fold
change induced by CBU-028. c, A heat map representation of genes whose expression is affected by EerI, 5-NA, or CBU-028. Both significantly up- or
down-regulated genes (.2 fold, p value ,0.05) are included. Note that clustering analysis indicates that CBU-028 resemble EerI more than 5-NA. d,
CBU-028 also accumulated at a perinuclear reticulum-like compartment. HeLa cells were treated with 10 mM CBU-028 and imaged by a fluorescence
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among this ATPase family. Nonetheless, the NFC domain of EerI
appears to be able to discriminate between p97 and a closely related
protein NSF. This suggests that EerI is unlikely to substantially
affect the functions of other AAA proteins in cells. A recent study
suggested that EerI may also target the Sec61 complex to inhibit
protein translocation into the ER [38]. The reported inhibition of
protein translocation in vitro requires a high concentration of EerI
(IC50.70 mM). At such a high concentration, the drug may have
non-specific interactions. Inhibition of ER protein expression was
observed in intact cells treated with 5–10 mM EerI [38]. This might
be due to reduced protein translocation or translation as a con-
sequence of ER stress induction, as demonstrated previously
[14,39]. Alternatively, the enrichment of EerI, a compound with
a hydrophobic membrane binding moiety, in the ER membrane
may alter the fluidity of the membrane to indirectly affect protein
import into the ER. Indeed, it has been demonstrated that loading
the ER with cholesterol inhibits protein translocation [40]. Future
studies will be required to clarify whether or not EerI can also
directly target the Sec61 complex.
Membrane localization and target specificity
Nitrofurans define a class of compounds with the signature
component of a furan ring and a nitro group. The NFC domain in
EerI corresponds to 5-nitrofuryl-acrolein (5-NA), which is an
unsaturated aldehyde carrying a nitrofuran group. Early studies
demonstrated that 5-NA and its structurally related compounds are
highly mutagenic [41,42]. We demonstrate here that the NFC
domain in EerI is capable of interacting with p97, which explains
the observed effect of 5-NA on ERAD. However, consistent with
early toxicity studies, the effect of 5-NA on cells appears to be
pleiotropic as it also affects many pathways unrelated to ER
homeostasis. Gene expression studies show that most genes
activated by 5-NA are not p97 signature genes, suggesting that it
can target other proteins in addition to p97. Interestingly, the
addition of the aromatic domain to 5-NA alters its target specificity,
making the resulting compound EerI a more specific inhibitor for
ER homeostasis. Compared with 5-NA, EerI only influences the
expression of a small set of genes, most of which result from ER
stress induction. Our qRT-PCR analyses estimate that at least 50%
of genes affected by EerI are p97 signature genes, suggesting that
p97 is a primary target of EerI. The localization of EerI to the ER
membrane by the aromatic domain appears to be responsible for
the improved target specificity because replacing this domain with
another benzene-containing moiety that has a moderate affinity for
the ER membrane produces a compound that has activities closely
resemblingEerI.Thelocalization ofEerItotheERseemstolimitits
action to only membrane-bound p97. This can explain why ERAD
inhibition and ER stress are the two major phenotypes of cells
exposed to EerI even though p97 is abundant in the cytosol and
have functions unrelated to the ERAD [23,43,44,45]. The aromatic
domain of EerI may also improve targeting specificity by restricting
EerI from interacting with cellular targets of 5-NA either as a result
of its membrane association or steric hindrance.
In summary, our studies uncover a class of bifunctional
compounds that associate with the ER membrane to disrupt ER
homeostasis. We propose that localizing compounds to the ER
membrane may be an effective strategy to improve the specificity
for cancer therapeutics that targets ER homeostasis.
Materials and Methods
Proteins, antibodies, and chemicals
Wild type p97 and mutant proteins were purified as previously
described [46]. Hsp70 protein was purchased from Assay Designs,
Inc. (Ann Arbor, MI). Immunoblotting experiments were carried
out using the following antibodies: FLAG antibody (Sigma),
NOXA antibody (EMD), ATF3 (Santa Cruz), histone H2A
(Abcam). The ATF4 antibody was described previously [32]. EerI
was synthesized by the NIDDK Chemical Biology Core facility. 5-
NA was purchased from TCI America. The synthetic protocols for
the hydrazone library and EerI will be reported elsewhere. EerI
can also be purchased from Chembridge Corporation (San Diego,
CA) or Tocris Bioscience (Ellisville, MO). Control siRNA and the
Smart pool siRNA targeting p97 were purchased from Dharma-
con (Lafayette, CO).
Mammalian cell experiments
HeLa and 293T cells from ATCC were maintained according
to the standard procedures. JEKO-1 cells were kept in RPMI,
10% FCS as previously described. NOXA and control stable
knock-down JEKO-1 cells were described previously [32]. PBMC
from normal volunteers were obtained from the Department of
Transfusion Medicine, NIH and PBMC from CLL patients were
obtained under NIH protocol 97-C-0178 with informed consent.
Transfection was done with lipofectamine 2000 (Invitrogen) for
293T accordingly to manufacture’s instruction. Pulse chase and
denaturing immunoprecipitation were carried out as described
previously [47,48]. Subcellular fractionation experiments were
carried out as previously described [49]. Briefly, HeLa cells were
harvested and washed with phosphate-buffered saline. Cells were
then treated on ice with the buffer PB (25 mM Hepes, pH 7.2,
115 mM potassium acetate, 5 mM sodium acetate, 2.5 mM mag-
nesium acetate, 0.5 mM EGTA, and a protease inhibitor cocktail)
that also contain 0.028% digitonin. Cells were centrifuged at
20,0006g for 10 min. The cytosolic supernatant fraction was
removed and the nucleus and membrane pellet fraction was
washed twice with the PB buffer. The pellet fraction was finally
resuspended in the PB buffer. The fluorescence intensity in these
fractions was measured by the Victor 3 plate reader using the
Ex482 and Em523 filter set. Cell viability assay were performed
using the MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyl tetra-
sodium bromide) reagent (Chemicon, Temecula, CA) as described
previously [50]. Briefly, JEKO-1 cells were incubated with the
drugs at the indicated concentration for 48 h. MTT was added to
the medium at the concentration of 0.5 mg/ml. After 4 h
incubation, the sample absorbance at 570 nM and 650 nM were
measured using a Victor 3 plate reader (Perkin Elmer, Waltham,
MA) and ratio of drug-treated samples vs. the untreated control
was used to determine cell viability. Immunoblotting experiments
were performed according to standard protocol. Fluorescence
labeled secondary antibodies (Invitrogen, Carlsbad, CA) were used
microscope. e, Subcellular fractionation analysis shows that CBU-028 is moderately enriched in the membrane. HeLa cells exposed to the indicated
compounds were permeabilized and then fractionated into a supernatant fraction containing the cytosol and a pellet fraction comprising the ER
membrane and the nucleus. The distribution of the indicated proteins in these fractions was determined by immunoblotting. The fluorescence signal
in the fractions was measured by a fluorimeter. The signal in the corresponding fractions from untreated control cells was taken as the background.
Shown is the ratio between the fluorescence signal in the pellet fraction and that in the cytosol. Error bars represent the average of two independent
experiments.
doi:10.1371/journal.pone.0015479.g008
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LI-COR Odyssey infrared imager using the software provided by
the manufacture. Fluorescence images were obtained using a Zeiss
Axiovert200 fluorescence microscope equipped with a 63X oil
immersion Plan Apochromat objective and standard filter sets
(FITC and rhodamine).
Co-precipitation experiment
B-NFC was immobilized on monomeric avidin beads by
incubating 50 mM compound with the beads in a binding buffer
containing 10 mM HEPES, pH 7.2, 150 mM sodium chloride,
0.005% Surfactant P20. The beads were then incubated with the
0.5 mM purified p97 proteins in 500 ml binding buffer at 4 degree
for 1 h. The beads were washed for 3 times with the binding buffer
and bound materials were eluated by incubating the beads with
binding buffer comprising 4 mM biotin.
RNA preparation, array hybridization and qRT-PCR
CellsweretreatedwithEerI,CBU-028,or5-NAeachat10 mMin
duplicates for 10 h. Total RNA was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA), and subsequently purified using an
RNeasy MinElute Cleanup kit (QIAGEN, Valencia, CA). For array
hybridization, RNA samples were processed and analyzed by the
NIDDK Microarray Core Facility. Affymetrix gene expression
analysis array for the human HG-U133A_2_0 were used (Affyme-
trix). The microarray signals were analyzed using the Affymetrix
RMA algorithm.Up- and down-regulated genes wereselected based
on P values of ,0.05 and fold change .2.0 or ,22.0 as assessed
by ANOVA with Partek Pro software (Partek). Genes that were
upregulated by .1.5 were sometimes used in analysis as indicated in
the figure legend. To determine specific pathways, gene pathway
analysis were conducted using the Genego program available at
http://trials.genego.com/cgi/index.cgi using the statistical signifi-
cant ANOVA gene list (p,0.05, fold change.1.5) represented on
the chip. Microarray data is MIAME compliant and that the raw
data has been deposited in the Gene Expression Omnibus (GEO)
database (accession no. GSE23849) (http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=xjkpxkuiiyameho&acc=GSE23849).
For quantitative RT-PCR, cDNA was synthesized using the
SuperScript
TM First-Strand kit (Invitrogen, Carlsbad, CA). Real-
time PCR was performed in triplicate using the SYBR green PCR
Master mixture. b-actin was used for normalization.
Surface plasmon resonance (SPR) interaction analysis
Surface plasmon resonance interaction experiments were
carried out at 25 degree on a Biacore T100 system (GE health-
care). Recombinant wild type or mutant p97 was covalently
attached to a carboxymethyl dextran-coated gold surface (CM5
Chip; GE healthcare) using an amide couple kit following a
manufacture suggested protocol. Briefly, the carboxymethyl group
of dextran was activated with N-ethyl-N’-(3-dimethylaminopropyl)
carbodiimide (EDC) and N-hydroxysuccinimide (NHS). p97 in a
buffer containing 10 mM sodium acetate (pH 4.5) was injected at
a flow rate of 10 ml/min with 2 min contact time and p97 was
immobilized at a level of ,8,000RU. Any remaining reactive
sites in the flow cell were blocked by ethanolamine. The drug
association and dissociation were monitored at a flow rate of
20 mL/min with the compound concentration ranging from
3.125 mMt o5 0 mM. Analysts were prepared in a buffer
containing 10 mM HEPES (pH 7.4), 150 mM NaCl, 0,005% v/v
Surfactant P20. Regeneration was achieved by extended washing
with the analyte buffer. SPR signal was normalized using a
reference flow cell containing no p97. For each compound, three
independent measurements were made. To calculate the affinity of
EerI to p97, we fitted the data from each binding experiment with a
Michaelis-Menton model using the KaleidaGraph software. The
Rmax was then calculated, and the binding relative to the Rmax
from three independent experiments was averaged. The averaged
binding data were used to calculate the Kd.
Limited trypsin digestion experiment
The purified p97 protein (1.5 mg) was incubated at in a buffer
containing 200 ng trypsin in 50 ml volume. Samples were taken
out at different time points and mixed with the Laemmli buffer
before SDS-PAGE and silver staining analyses.
Supporting Information
Figure S1 SPR analysis of EerI-p97 interaction. Repre-
sentative binding curves show direct binding of EerI to p97. R.U.
response unit.
Figure S2 Induction of ER stress and NOXA expression
by EerI and 5-NA. 293T cells were treated with various com-
pounds at the indicated concentration for 8 h. Whole cell extract was
analyzed by immunoblotting with the indicated antibodies.
Figure S3 5-NA but not CBU-002 inhibits the degrada-
tion of MHC class I heavy chain in US11 cells. US11 cells
treated with the indicated compound (10 mM) were pulse labeled
in a medium containing 35S-Met/Cyc then incubated in a chase
medium containing excess unlabeled Met/Cys. MHC class I
heavy chain was immunoprecipitated from cell extract and
analyzed by SDS–PAGE and autoradiography.
Figure S4 Pathway analyses of EerI and 5-NA signature
genes. Genes with fold change $1.5 from ANOVA analysis (p
value #0.05) were used for pathway analyses by the commercial
software MetaCore. Shown is a histogram indicating the top 10
cellular processes significantly represented by genes affected by
both Eer1 and 5-NA. For comparison, the relative representation
of the corresponding pathway by the unique genes for 5-NA or
Eer1 was shown in red and in blue, respectively.
Table S1 A list of genes whose expression is signifi-
cantly affected by EerI or 5-NA. (Fold change .1.5, p value
,0.05 from a biological replicate).
Table S2 A list of compounds tested in this study. JEKO-
1 cells were treated with each of the listed compounds at
concentrations ranging from 1.25 mMt o2 0mM. Cell viability was
determined by the MTT assay and used to obtain concentration-
response curve. IC50 was extracted by linear interpolation.
Acknowledgments
We thank Colby Chapman (NHLBI) for technical support, Hemmo Meyer
(University of Duisburg-Essen) for reagents, Michael Krause and Tom
Rapoport for critical reading of the manuscript.
Author Contributions
Conceived and designed the experiments: QW WT AW YY. Performed
the experiments: QW BS JL YL MW. Analyzed the data: QW WT WC
AW YY. Wrote the paper: YY.
References
1. Schroder M, Kaufman RJ (2005) The mammalian unfolded protein response.
Annu Rev Biochem 74: 739–789.
2. Ron D, Walter P (2007) Signal integration in the endoplasmic reticulum
unfolded protein response. Nat Rev Mol Cell Biol 8: 519–529.
EerI Targets Membrane-Associated p97
PLoS ONE | www.plosone.org 11 November 2010 | Volume 5 | Issue 11 | e154793. Ameri K, Lewis CE, Raida M, Sowter H, Hai T, et al. (2004) Anoxic induction
of ATF-4 through HIF-1-independent pathways of protein stabilization in
human cancer cells. Blood 103: 1876–1882.
4. Blais JD, Filipenko V, Bi M, Harding HP, Ron D, et al. (2004) Activating
transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol
24: 7469–7482.
5. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee AH, et al. (2004)
XBP1 is essential for survival under hypoxic conditions and is required for tumor
growth. Cancer Res 64: 5943–5947.
6. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, et al. (2005) ER stress-regulated
translation increases tolerance to extreme hypoxia and promotes tumor growth.
Embo J 24: 3470–3481.
7. Ma Y, Hendershot LM (2004) The role of the unfolded protein response in
tumour development: friend or foe? Nat Rev Cancer 4: 966–977.
8. Koumenis C (2006) ER stress, hypoxia tolerance and tumor progression. Curr
Mol Med 6: 55–69.
9. Balch WE, Morimoto RI, Dillin A, Kelly JW (2008) Adapting proteostasis for
disease intervention. Science 319: 916–919.
10. Nishitoh H, Matsuzawa A, Tobiume K, Saegusa K, Takeda K, et al. (2002)
ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death
triggered by expanded polyglutamine repeats. Genes Dev 16: 1345–1355.
11. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, et al. (2007) IRE1 signaling
affects cell fate during the unfolded protein response. Science 318: 944–949.
12. Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, et al. (2007) ER stress
triggers apoptosis by activating BH3-only protein Bim. Cell 129: 1337–1349.
13. Wang XZ, Lawson B, Brewer JW, Zinszner H, Sanjay A, et al. (1996) Signals
from the stressed endoplasmic reticulum induce C/EBP-homologous protein
(CHOP/GADD153). Mol Cell Biol 16: 4273–4280.
14. Kang SW, Rane NS, Kim SJ, Garrison JL, Taunton J, et al. (2006) Substrate-
specific translocational attenuation during ER stress defines a pre-emptive
quality control pathway. Cell 127: 999–1013.
15. Tsai B, Ye Y, Rapoport TA (2002) Retro-translocation of proteins from the
endoplasmic reticulum into the cytosol. Nat Rev Mol Cell Biol 3: 246–255.
16. Ye Y (2005) The role of the ubiquitin-proteasome system in ER quality control.
Essays Biochem 41: 99–112.
17. Meusser B, Hirsch C, Jarosch E, Sommer T (2005) ERAD: the long road to
destruction. Nat Cell Biol 7: 766–772.
18. Vembar SS, Brodsky JL (2008) One step at a time: endoplasmic reticulum-
associated degradation. Nat Rev Mol Cell Biol 9: 944–957.
19. Nakatsukasa K, Brodsky JL (2008) The recognition and retrotranslocation of
misfolded proteins from the endoplasmic reticulum. Traffic 9: 861–870.
20. Kostova Z, Tsai YC, Weissman AM (2007) Ubiquitin ligases, critical mediators
of endoplasmic reticulum-associated degradation. Semin Cell Dev Biol 18:
770–779.
21. Hirsch C, Gauss R, Horn SC, Neuber O, Sommer T (2009) The ubiquitylation
machinery of the endoplasmic reticulum. Nature 458: 453–460.
22. Ye Y, Meyer HH, Rapoport TA (2001) The AAA ATPase Cdc48/p97 and its
partners transport proteins from the ER into the cytosol. Nature 414: 652–656.
23. Ye Y (2006) Diverse functions with a common regulator: ubiquitin takes
command of an AAA ATPase. J Struct Biol 156: 29–40.
24. Adams J (2004) The development of proteasome inhibitors as anticancer drugs.
Cancer Cell 5: 417–421.
25. Fribley A, Zeng Q, Wang CY (2004) Proteasome inhibitor PS-341 induces
apoptosis through induction of endoplasmic reticulum stress-reactive oxygen
species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24:
9695–9704.
26. Fribley AM, Evenchik B, Zeng Q, Park BK, Guan JY, et al. (2006) Proteasome
inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell
carcinoma cells by induction of Noxa. J Biol Chem 281: 31440–31447.
27. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, et al. (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple
myeloma cells. Blood 107: 4907–4916.
28. Fels DR, Ye J, Segan AT, Kridel SJ, Spiotto M, et al. (2008) Preferential
cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of
endoplasmic reticulum stress pathways. Cancer Res 68: 9323–9330.
29. Armstrong JL, Flockhart R, Veal GJ, Lovat PE, Redfern CP (2009) Regulation
of ER stress-induced cell death by ATF4 in neuroectodermal tumour cells. J Biol
Chem.
30. Szokalska A, Makowski M, Nowis D, Wilczynski GM, Kujawa M, et al. (2009)
Proteasome inhibition potentiates antitumor effects of photodynamic therapy in
mice through induction of endoplasmic reticulum stress and unfolded protein
response. Cancer Res 69: 4235–4243.
31. Wang Q, Li L, Ye Y (2008) Inhibition of p97-dependent protein degradation by
Eeyarestatin I. J Biol Chem.
32. Wang Q, Mora-Jensen H, Weniger MA, Perez-Galan P, Wolford C, et al. (2009)
ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate
BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A 106:
2200–2205.
33. Halawani D, LeBlanc AC, Rouiller I, Michnick SW, Servant MJ, et al. (2009)
Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2
domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring
conformation. Mol Cell Biol 29: 4484–4494.
34. Wiertz EJ, Jones TR, Sun L, Bogyo M, Geuze HJ, et al. (1996) The human
cytomegalovirus US11 gene product dislocates MHC class I heavy chains from
the endoplasmic reticulum to the cytosol. Cell 84: 769–779.
35. Ye Y, Shibata Y, Yun C, Ron D, Rapoport TA (2004) A membrane protein
complex mediates retro-translocation from the ER lumen into the cytosol.
Nature 429: 841–847.
36. Lilley BN, Ploegh HL (2004) A membrane protein required for dislocation of
misfolded proteins from the ER. Nature 429: 834–840.
37. Fiebiger E, Hirsch C, Vyas JM, Gordon E, Ploegh HL, et al. (2004) Dissection of
the dislocation pathway for type I membrane proteins with a new small molecule
inhibitor, eeyarestatin. Mol Biol Cell 15: 1635–1646.
38. Cross BC, McKibbin C, Callan AC, Roboti P, Piacenti M, et al. (2009)
Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic
reticulum. J Cell Sci 122: 4393–4400.
39. Harding HP, Zhang Y, Ron D (1999) Protein translation and folding are
coupled by an endoplasmic-reticulum-resident kinase. Nature 397: 271–274.
40. Nilsson I, Ohvo-Rekila H, Slotte JP, Johnson AE, von Heijne G (2001)
Inhibition of protein translocation across the endoplasmic reticulum membrane
by sterols. J Biol Chem 276: 41748–41754.
41. Eder E, Deininger C, Muth D (1991) Genotoxicity of p-nitrocinnamaldehyde
and related alpha, beta-unsaturated carbonyl compounds in two bacterial assays.
Mutagenesis 6: 261–269.
42. Borroto JI, Creus A, Marcos R (2002) Genotoxic evaluation of the furylethylene
derivative 1-(5-bromofur-2-yl)-2-nitroethene in cultured human lymphocytes.
Mutat Res 519: 179–185.
43. Mouysset J, Deichsel A, Moser S, Hoege C, Hyman AA, et al. (2008) Cell cycle
progression requires the CDC-48UFD-1/NPL-4 complex for efficient DNA
replication. Proc Natl Acad Sci U S A 105: 12879–12884.
44. Ramadan K, Bruderer R, Spiga FM, Popp O, Baur T, et al. (2007) Cdc48/p97
promotes reformation of the nucleus by extracting the kinase Aurora B from
chromatin. Nature 450: 1258–1262.
45. Wilcox AJ, Laney JD (2009) A ubiquitin-selective AAA-ATPase mediates
transcriptional switching by remodelling a repressor-promoter DNA complex.
Nat Cell Biol 11: 1481–1486.
46. Ye Y, Meyer HH, Rapoport TA (2003) Function of the p97-Ufd1-Npl4 complex
in retrotranslocation from the ER to the cytosol: dual recognition of
nonubiquitinated polypeptide segments and polyubiquitin chains. J Cell Biol
162: 71–84.
47. Wang Q, Li L, Ye Y (2006) Regulation of retrotranslocation by p97-associated
deubiquitinating enzyme ataxin-3. J Cell Biol 174: 963–971.
48. Flierman D, Ye Y, Dai M, Chau V, Rapoport TA (2003) Polyubiquitin serves as
a recognition signal, rather than a ratcheting molecule, during retrotranslocation
of proteins across the endoplasmic reticulum membrane. J Biol Chem 278:
34774–34782.
49. Shamu CE, Story CM, Rapoport TA, Ploegh HL (1999) The pathway of US11-
dependent degradation of MHC class I heavy chains involves a ubiquitin-
conjugated intermediate. J Cell Biol 147: 45–58.
50. Rizzatti EG, Mora-Jensen H, Weniger MA, Gibellini F, Lee E, et al. (2008)
Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically
resistant mantle cell lymphoma cells and this effect is independent of constitutive
activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 49: 798–808.
EerI Targets Membrane-Associated p97
PLoS ONE | www.plosone.org 12 November 2010 | Volume 5 | Issue 11 | e15479